Basis for good reliance on reference assessments of medicinal products for 2025

Published By : Jordan Food and Drug Administration | Consultation Type : Other | Consultation was extended to 3/1/2026 For To obtain broader feedback

Health

Closed

Published Consultation

1/22/2026
Comment End Date

3/1/2026
Consultation Definition

3/2/2026
Consultation Results

3/10/2026

Subject of consultation
Activities
Full legal text

Objectives

The institution aims, through the implementation of these principles, to enhance the speed of access to safe and effective medicines for patients, while improving work efficiency by relying on the best internationally recognized standards and guidelines in this field.

Summary

The Good Reliance Practices for the Assessment of Reference Authorities for Pharmaceutical Products for the year 2025 apply to pharmaceutical products and encompass all regulatory procedures throughout the product lifecycle, including registration and granting of marketing authorization, pharmacovigilance, post-marketing surveillance and inspection, as well as the accreditation of manufacturing sites and their re-evaluation.